Javascript must be enabled to continue!
Oral Nifidepine versus IV labetalol in severe preeclampsia: A randomized control trial
View through CrossRef
Objective: To compare oral Nifidepine and IV labetalol in terms of rapidity of BP control in severe preeclampsia.
Methods: All patients coming to Services Hospital from March 2017 to February 2019 with diagnosis of severe preeclampsia ≥ 24 weeks gestation were randomized to either receive Nifidepine or Labetalol. Primary outcome measure was time taken to control BP and number of doses required. Secondary outcome measures were side effects of drugs, APGAR score, NICU admission and perinatal mortality.
Results: Two hundred four patients were included in trial with 102 patients in each group. Labetalol took 22.6± 13.5minutes and Nifidepine took 22.09± 11.7 minutes to achieve target BP (p>0.05). Labetalol required 2.3± 1.58 doses and Nifidepine 2.2± 1.58 doses to control BP ( p>0.05). No maternal side effects were seen in 86 (84.31%) and 92(90.19%) patients in both groups (p>0.05). Mean gestational age at birth was 34.8 ±2.73weeks in Labetalol and 35.2±2.48 weeks in Nifidepine group (p>0.05). In labetalol group, 43 (42.15%) babies had APGAR Score < 7/10 and 23(22.54%) babies required admission to NICU while in Nifidepine group 42 (41.17%) babies had Apgar score < 7/10 & 30(29.4%) babies were admitted to NICU(p>0.05). There were 21(20.5%) perinatal deaths in labetalol Group-And 19(18.6%) in Nifidepine group (p>0.05)
Conclusion: Oral Nifidepine and IV labetalol are equally efficacious in controlling BP in patients with severe pre eclampsia without any significant side effects.
doi: https://doi.org/10.12669/pjms.36.6.2591
How to cite this:Wasim T, Agha S, Saeed K, Riaz A. Oral Nifidepine versus IV labetalol in severe preeclampsia: A randomized control trial. Pak J Med Sci. 2020;36(6):1147-1152. doi: https://doi.org/10.12669/pjms.36.6.2591
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pakistan Journal of Medical Sciences
Title: Oral Nifidepine versus IV labetalol in severe preeclampsia: A randomized control trial
Description:
Objective: To compare oral Nifidepine and IV labetalol in terms of rapidity of BP control in severe preeclampsia.
Methods: All patients coming to Services Hospital from March 2017 to February 2019 with diagnosis of severe preeclampsia ≥ 24 weeks gestation were randomized to either receive Nifidepine or Labetalol.
Primary outcome measure was time taken to control BP and number of doses required.
Secondary outcome measures were side effects of drugs, APGAR score, NICU admission and perinatal mortality.
Results: Two hundred four patients were included in trial with 102 patients in each group.
Labetalol took 22.
6± 13.
5minutes and Nifidepine took 22.
09± 11.
7 minutes to achieve target BP (p>0.
05).
Labetalol required 2.
3± 1.
58 doses and Nifidepine 2.
2± 1.
58 doses to control BP ( p>0.
05).
No maternal side effects were seen in 86 (84.
31%) and 92(90.
19%) patients in both groups (p>0.
05).
Mean gestational age at birth was 34.
8 ±2.
73weeks in Labetalol and 35.
2±2.
48 weeks in Nifidepine group (p>0.
05).
In labetalol group, 43 (42.
15%) babies had APGAR Score < 7/10 and 23(22.
54%) babies required admission to NICU while in Nifidepine group 42 (41.
17%) babies had Apgar score < 7/10 & 30(29.
4%) babies were admitted to NICU(p>0.
05).
There were 21(20.
5%) perinatal deaths in labetalol Group-And 19(18.
6%) in Nifidepine group (p>0.
05)
Conclusion: Oral Nifidepine and IV labetalol are equally efficacious in controlling BP in patients with severe pre eclampsia without any significant side effects.
doi: https://doi.
org/10.
12669/pjms.
36.
6.
2591
How to cite this:Wasim T, Agha S, Saeed K, Riaz A.
Oral Nifidepine versus IV labetalol in severe preeclampsia: A randomized control trial.
Pak J Med Sci.
2020;36(6):1147-1152.
doi: https://doi.
org/10.
12669/pjms.
36.
6.
2591
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.
org/licenses/by/3.
0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Related Results
Efficacy of oral Labetalol vs Nifedipine in the management of severe hypertension in pregnancy. A Randomized Controlled Trial
Efficacy of oral Labetalol vs Nifedipine in the management of severe hypertension in pregnancy. A Randomized Controlled Trial
Abstract
Hypertensive disorders in pregnancy (HDP) are leading causes of pregnancy-related morbidity and mortality. International guidelines have recommended the us...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Comparative Efficacy of Labetalol and Methyldopa in the Management of Pregnancy-Induced Hypertension
Comparative Efficacy of Labetalol and Methyldopa in the Management of Pregnancy-Induced Hypertension
Background: Pregnancy-induced hypertension (PIH) is a common obstetric complication marked by elevated blood pressure after 20 weeks of gestation, affecting 5–10% of pregnancies wo...
A Comparative Study of Oral Nifedipine and Intravenous Labetalol for Acute Hypertensive Management in Pregnancy: Assessing Feto-Maternal Outcomes in a Hospital-based Randomized Control Trial
A Comparative Study of Oral Nifedipine and Intravenous Labetalol for Acute Hypertensive Management in Pregnancy: Assessing Feto-Maternal Outcomes in a Hospital-based Randomized Control Trial
Background and Objective
Hypertension is one of the most common medical complications during pregnancy and a leading cause of maternal mo...
The dose dependency of the alpha‐adrenoceptor antagonist and beta‐ adrenoceptor partial agonist activity of dilevalol and labetalol in man.
The dose dependency of the alpha‐adrenoceptor antagonist and beta‐ adrenoceptor partial agonist activity of dilevalol and labetalol in man.
1. The alpha‐adrenoceptor antagonist, beta 1‐adrenoceptor antagonist and beta 2‐partial agonist activity of dilevalol, a beta‐adrenoceptor antagonist with vasodilating properties a...
Effect of perioperative magnesium sulfate and labetalol infusion on peripheral perfusion and postoperative pain in nasal surgery: a randomized controlled trial
Effect of perioperative magnesium sulfate and labetalol infusion on peripheral perfusion and postoperative pain in nasal surgery: a randomized controlled trial
Abstract
Background
Maintenance of adequate peripheral perfusion during controlled hypotension is necessary for patient s...
Identification of a rational, physiologically based early biomarker and pathogenic pathway For preeclampsia
Identification of a rational, physiologically based early biomarker and pathogenic pathway For preeclampsia
<p>Preeclampsia is a hypertensive disorder of pregnancy that is diagnosed after the 20th week of gestation. It is defined by the American College of Obstetrics and Gynecology...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...

